克隆 CR3022(产自本氏烟草)(单克隆抗体），NR-1_Vaccinia virus

NR-53876?? Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana)(Monoclonal Antibodies)|SARS Coronavirus|Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana)| -60°C or colder |Novici Biotech LLCAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana), NR-53876.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. Antibody Class: IgG1 Human monoclonal antibody CR3022 was prepared via an immune phage display library, constructed from lymphocytes of a convalescent severe acute respiratory syndrome coronavirus (SARS-CoV) patient. CR3022 is a neutralizing antibody that targets the receptor binding domain (RBD) of the spike (S) glycoprotein of SARS-CoV. NR-53876 was produced in Nicotiana benthamiana tobacco plants using a transient plant expression system and purified from the total plant homogenate using protein A chromatography. This antibody preparation differs from BEI Resources NR-52392 only in the method used to extract the recombinant product from the expression host plants prior to affinity purification; NR-52392 was purified from an extracellular fraction and NR-53876 was extracted from total plant homogenate. Plant made antibody CR3022 features complementarity-determining region (CDR) sequences introduced into a human IgG1 molecule. The epitope of CR3022 does not overlap with the ACE2-binding site within the S glycoprotein RBD from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). CR3022 targets a highly conserved epitope that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV. Note: Questions related to NR-53876 may be addressed by contacting info@novicibiotech.com. NR-53876 is specific to the S glycoprotein and has been shown to neutralize SARS-CoV. CR3022 recognizes the full-length SARS-CoV-2 S1 protein fused to a human IgG1 Fc domain (S1-Fc) under reducing and non-reducing conditions, as well as a hexa-histidine-tagged S glycoprotein RBD alone, in Western blot analysis; however, CR3022 did not neutralize SARS-CoV-2 in a recent in vitro assay. CR3022 binds potently to SARS-CoV-2 RBD as determined by ELISA and biolayer interferometry (BLI) binding assays. Applications include western blot analysis, immunofluorescence, ELISA and neutralization. Each vial of NR-53876 contains approximately 100 ?L of purified monoclonal antibody in PBS.

NR-52392?? Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana)(Monoclonal Antibodies)|SARS Coronavirus|Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana)| -60°C or colder |Novici Biotech LLCAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-SARS Coronavirus Recombinant Human IgG1, Clone CR3022 (produced in Nicotiana benthamiana), NR-52392.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. Antibody Class: IgG1 Human monoclonal antibody CR3022 was prepared via an immune phage display library, constructed from lymphocytes of a convalescent severe acute respiratory syndrome coronavirus (SARS-CoV) patient. CR3022 is a neutralizing antibody that targets the receptor binding domain (RBD) of the spike (S) glycoprotein of SARS-CoV. NR-52392 was produced in Nicotiana benthamiana tobacco plants using a transient plant expression system and purified from the extracellular fraction using protein A chromatography. Plant-made antibody CR3022 features complementarity-determining region (CDR) sequences introduced into a human IgG1 molecule. The epitope of CR3022 does not overlap with the ACE2-binding site within the S glycoprotein RBD from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). CR3022 targets a highly conserved epitope that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV. Note: Questions related to NR-52392 may be addressed by contacting info@novicibiotech.com. NR-52392 is specific to the S glycoprotein and has been shown to neutralize SARS-CoV. CR3022 recognizes the full-length SARS-CoV-2 S1 protein fused to a human IgG1 Fc domain (S1-Fc) under reducing and non-reducing conditions, as well as a hexa-histidine-tagged S glycoprotein RBD alone, in Western blot analysis; however, CR3022 did not neutralize SARS-CoV-2 in a recent in vitro assay. CR3022 binds potently to SARS-CoV-2 RBD as determined by ELISA and biolayer interferometry (BLI) binding assays. Applications include western blot analysis, immunofluorescence, ELISA and neutralization. Each vial of NR-52392 contains approximately 50 ?L of purified monoclonal antibody in PBS.